- Advertisement -

Efficacy of Polyfunctional GD3 CAR T Cells against Rare Tumors

REGISTER NOW   Broadcast Date: March 8, 2022Time: 8:00 am PT, 11:00 am ET, 16:00 CET Tuberous sclerosis complex (TSC) is a rare genetic disorder that...

Navigating Evolving mRNA Challenges with the Right Partner

The market for mRNA vaccines has experienced a surge fueled by the global rollout of the COVID-19 vaccines, and the potential of mRNA technology...

Illinois Tech grows research footprint, securing prime space at TCC’s Fulton Labs

CHICAGO—November 3, 2023—Illinois Institute of Technology (Illinois Tech) has leased approximately 34,295 square feet in Trammell Crow Company’s (TCC) Fulton Labs innovation hub, announced today...

Gloucester Biotechnology Academy graduates new crop of biotech lab techs –...

Jun. 25—Gloucester Biotechnology Academy Class of 2022 student speaker Colby Delano of Ipswich said he felt stuck before applying to the academy's Biotechnology Certificate...

The Next Wave of ADC Innovation: The Science Behind Dual-Payload Bioconjugates

Register Now Cindy Cheng Executive Director, Head of New Technology DiscoveryWuXi XDC View...

New method for assessing the structural changes in cardiac arrhythmia

A multidisciplinary study led by scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) presents a new method for assessing the structural and electrophysiological...

Manus and UT Austin Advance Biomanufacturing Product Recovery Through BioMADE Program

Manus, The BioAlternatives Company®, and the University of Texas at Austin say they have completed a BioMADE-sponsored program to make industrial yeast fermentation more...

The Emerging Power of Mass Spectrometry in Oncology

Globally, the incidence of newly diagnosed cancer cases is projected to increase over the next decade.1 Despite advancements in personalized medicine and therapeutic options,...

Manus and UT Austin Advance Biomanufacturing Product Recovery Through BioMADE Program

Manus, The BioAlternatives Company®, and the University of Texas at Austin say they have completed a BioMADE-sponsored program to make industrial yeast fermentation more...

The Emerging Power of Mass Spectrometry in Oncology

Globally, the incidence of newly diagnosed cancer cases is projected to increase over the next decade.1 Despite advancements in personalized medicine and therapeutic options,...

Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase III Trial

Novartis shares fell the most in a single day since the COVID-19 pandemic after the pharma giant acknowledged that its neuromuscular candidate delpacibart etedesiran...

more new items

Manus and UT Austin Advance Biomanufacturing Product Recovery Through BioMADE Program

Manus, The BioAlternatives Company®, and the University of Texas at Austin say they have completed a BioMADE-sponsored program to make industrial yeast fermentation more...

The Emerging Power of Mass Spectrometry in Oncology

Globally, the incidence of newly diagnosed cancer cases is projected to increase over the next decade.1 Despite advancements in personalized medicine and therapeutic options,...

Novartis Shares Slide After Neuromuscular Candidate Acquired with Avidity Fails Phase...

Novartis shares fell the most in a single day since the COVID-19 pandemic after the pharma giant acknowledged that its neuromuscular candidate delpacibart etedesiran...